3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
31
Neoplasms
17
Multiple Myeloma
9
Thyroid Neoplasms
8
Hematologic Neoplasms
7
Thyroid Carcinoma, Anaplastic
6
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
6
Lymphoma
5
Glioma
5
Colorectal Neoplasms
5
Thyroid Cancer, Papillary
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neurofibromatosis 1
3
Leukemia, Myeloid, Acute
3
Biliary Tract Neoplasms
3
Astrocytoma
3
Adenocarcinoma, Follicular
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Skin Neoplasms
2
Neurofibroma, Plexiform
2
Neoplasm Metastasis
2
Glioblastoma
2
Gastrointestinal Stromal Tumors
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
trametinib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled